<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941183</url>
  </required_header>
  <id_info>
    <org_study_id>NTR441-1001</org_study_id>
    <nct_id>NCT04941183</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blind, Single-ascending-dose and Multiple-ascending-dose, Phase 1 Study to Assess the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of IV NTR-441 Solution in HV Adults and COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neutrolis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neutrolis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first-in-human clinical study is a Phase 1a/ 1b, randomized, double-blind,&#xD;
      placebo-controlled study to assess the safety, tolerability, and PK/PD of NTR-441 in healthy&#xD;
      subjects and patients with COVID-19 after single ascending IV infusion doses and multiple&#xD;
      ascending IV infusion doses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo-controlled, double-blind, single-ascending-dose and multiple-ascending-dose</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate safety and tolerability of single and multiple ascending doses of NTR-441 solution administered intravenously (IV) to adults</measure>
    <time_frame>60 days</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 following a single or multiple IV of NTR-441.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of maximum plasma concentration (Cmax)</measure>
    <time_frame>15 days</time_frame>
    <description>Maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of time of maximum plasma concentration (Tmax)</measure>
    <time_frame>14 days</time_frame>
    <description>Time of maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of area under the concentration-time curve</measure>
    <time_frame>15 days</time_frame>
    <description>Area under the concentration-time curve from predose to the time of the last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of the terminal elimination rate (λz)</measure>
    <time_frame>15 days</time_frame>
    <description>Terminal elimination rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of terminal elimination half-life (t½)</measure>
    <time_frame>15 days</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of total body clearance (CL/F)</measure>
    <time_frame>15 days</time_frame>
    <description>Total body clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of apparent volume of distribution</measure>
    <time_frame>15 days</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess for immunogenicity of NTR-441 following single ascending and multiples ascending doses of NTR-441 solution administered IV to adults</measure>
    <time_frame>30 days</time_frame>
    <description>Concentration of anti-drug antibodies of NTR-441 following single and multiples doses of NTR-441 solution administered IV</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>NTR-441</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending Dose; Multiple Ascending Dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single Ascending Dose; Multiple Ascending Dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NTR-441</intervention_name>
    <description>NTR-441</description>
    <arm_group_label>NTR-441</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy volunteers:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, non-smoker, ≥18 and ≤55 years of age, with Body Mass Index (BMI) &gt;&#xD;
             18.5 and &lt; 32.0 kg/m2&#xD;
&#xD;
          -  Healthy with no clinically significant findings, determined by medical evaluation&#xD;
             (medical history, physical examination, vital signs, 12-lead ECG, and clinical&#xD;
             laboratory evaluations) at Screening&#xD;
&#xD;
          -  Subject is able to understand and is willing to comply with all study requirements,&#xD;
             and willing to follow the instructions of the study staff.&#xD;
&#xD;
          -  Subject voluntarily agrees to participate in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, nursing, and/or breastfeeding.&#xD;
&#xD;
          -  Study participant has a history of an anaphylactic reaction.&#xD;
&#xD;
          -  Subject has used an investigational drug within 30 days (or 5 half-lives whichever is&#xD;
             longer) prior to the first dose of study drug.&#xD;
&#xD;
          -  Has received any prescription or nonprescription over-the-counter (except occasional&#xD;
             use of acetaminophen, paracetamol or ibuprofen) medication, topical medications,&#xD;
             vitamins, dietary or herbal during the last 14 days or 5 half-lives, whichever is&#xD;
             longer.&#xD;
&#xD;
          -  Subject has a positive urine test for drugs of abuse at the screening visit or&#xD;
             admission.&#xD;
&#xD;
          -  Regular consumption of alcohol within 6 months prior to Screening or use of illicit&#xD;
             substances within 3 months prior to screening.&#xD;
&#xD;
          -  Subject has positive test for SARS-CoV-2 infection, human immunodeficiency virus&#xD;
             (HIV), chronic or active hepatitis B, or active hepatitis C.&#xD;
&#xD;
          -  Donation or loss of blood or plasma within 4 weeks prior to initial dosing.&#xD;
&#xD;
          -  Subject has a history or current evidence of a serious and/or unstable cardiovascular,&#xD;
             respiratory, gastrointestinal, hematologic, autoimmune, mental or other medical&#xD;
             disorder, including cirrhosis or malignancy; a history of a psychiatric disorder that&#xD;
             will affect the subject's ability to participate in the study.&#xD;
&#xD;
          -  Subject has a clinically relevant abnormal ECG; abnormal laboratory values.&#xD;
&#xD;
          -  Subject has hypertension.&#xD;
&#xD;
        COVID-19 patients:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, non-smoker, ≥18 years of age.&#xD;
&#xD;
          -  Participant has active laboratory-confirmed SARS-CoV-2 infection.&#xD;
&#xD;
          -  Participant must be hospitalized for COVID-19 pneumonia.&#xD;
&#xD;
          -  Ability to provide informed consent personally, or by a legally acceptable&#xD;
             representative if the participant is unable to do so.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, nursing, and/or breastfeeding.&#xD;
&#xD;
          -  History of an anaphylactic reaction.&#xD;
&#xD;
          -  In the opinion of the clinical team, progression to death is imminent and inevitable&#xD;
             within the next 24 hours, irrespective of the provision of treatments.&#xD;
&#xD;
          -  Severely immune-compromised participants.&#xD;
&#xD;
          -  Participant known to test positive for human immunodeficiency virus (HIV), chronic or&#xD;
             active hepatitis B, or active hepatitis C.&#xD;
&#xD;
          -  Any other clinical conditions that in the opinion of the Investigator would make the&#xD;
             participants unsuitable for the study.&#xD;
&#xD;
          -  Prior treatment with any investigational drug therapy against coronavirus infection&#xD;
             within 5 half-lives, prior to enrollment&#xD;
&#xD;
          -  Participants who have received an experimental (or, in future, potentially a licensed)&#xD;
             immunization or remdesivir against coronavirus remain eligible.&#xD;
&#xD;
          -  Participation in another clinical study with the study intervention administered from&#xD;
             30 days or 5 half-lives whichever is longer.&#xD;
&#xD;
          -  Anticipated transfer to another hospital which is not a study site during the&#xD;
             intervention period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christa Firbas, Dr.</last_name>
    <phone>+43 1 40400 29850</phone>
    <email>christa.firbas@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Infectiology and Tropical Medicine</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heinz Burgmann, Univ. Dr.</last_name>
      <phone>+43 (0)1 40400 - 44400</phone>
      <email>heinz.burgmann@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Heinz Burgmann</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna, Department of Clinical Pharmacology</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Jilma, Univ. Prof. Dr.</last_name>
      <phone>+43 1 40400 29980</phone>
      <email>bernd.jilma@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Bernd Jilma, Univ. Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid 19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

